CAR-T cell therapy in systemic autoimmune rheumatic diseases
Authors:
J. Závada
Authors‘ workplace:
Revmatologická klinika 1. LF UK, Praha
; Revmatologický ústav Praha
Published in:
Čes. Revmatol., 32, 2024, No. 3, p. 94-99.
Category:
Overview Reports
Overview
CAR-T cell therapy, which involves T lymphocytes engineered with a chimeric antigen receptor (CAR-T), was initially developed for treating hematologic malignancies. However, it has also shown promising results in refractory systemic autoimmune rheumatic diseases (SARD). CAR-T therapy targets B lymphocytes, which play a crucial role in autoimmune processes. Preliminary clinical trials in patients with systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome have demonstrated significant clinical improvement, disappearance of autoantibodies, and the achievement of remission without the need for other immunosuppressive therapies. Nonetheless, CAR-T therapy also carries certain risks, such as cytokine release syndrome and neurotoxic side effects. Future challenges include the high costs and complexity of CAR-T cell production.
Keywords:
Systemic lupus erythematosus – CAR-T cell therapy – B lymphocyte – connective tissue di-seases
Sources
1. Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019; 11.
2. Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2021; 18: 1896–1903.
3. Mougiakakos D, Kronke G, Volkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. New England J Med. 2021; 385: 567–569.
4. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022; 28(10): 2124–2132.
5. Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell therapy in autoimmune disease – A case series with follow-up. N Engl J Med. 2024; 390(8): 687–700.
6. Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023; 82(8): 1117–1120.
7. Pecher AC, Hensen L, Klein R, et al. CD19-Targeting CAR T Cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 2023; 329(24): 2154–2162.
8. Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 2024; 187(18): 4890–4904.
9. Zhang W, Feng J, Cinquina A, et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Rev Rep. 2021; 17: 2120–2123.
10. Wang J, Alkrekshi A, Dasari S et al. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study. Bone Marrow Transplant. 2023; 58: 1223–1228.
11. Ohno R, Nakamura A. Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies – evidence, safety, and future directions. Semin Arthritis Rheum. 2024; 67: 152479.
12. Lyu X, Gupta L, Tholouli E, Chinoy H. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. Rheumatology (Oxford) 2024; 63(5): 1206–1216.
13. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet 2023; 402(10416): 2034–2044.
14. Appalaneni R, Achanta N, Mohan C. Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0. Curr Opin Rheumatol. 2024; 36(2): 126–133.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2024 Issue 3
Most read in this issue
- Principles of treating SLE according to the 2023 EULAR treatment recommendations update – commentary
- CAR-T cell therapy in systemic autoimmune rheumatic diseases
- Bimekizumab – the first dual inhibitor of IL-17A and IL-17F – a novel treatment for psoriatic arthritis and axial spondyloarthritis
- Editorial